early treatment

EARLY TREATMENT FOR COVID-19 AT MONOCLONAL ANTIBODY REGIONAL CENTERS (MARC)

Source: County of San Diego Health & Human Services Agency (HHSA)

Photo: Twitter @SanDiegoCounty

July 19, 2021 (San Diego) -- Monoclonal antibodies are proteins made in a lab that help boost the immune system to fight viruses. The monoclonal antibody combination treatments of monoclonal antibody combination treatment  from Regeneron has been authorized for emergency use to treat mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg / 88 lbs.) with positive results of direct SARS-CoV-2 (the virus that causes COVID-19) viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. Monoclonal antibodies have been shown in clinical trials to reduce COVID-19-related hospitalization and emergency room visits.


Error message

Support community news in the public interest! As nonprofit news, we rely on donations from the public to fund our reporting -- not special interests. Please donate to sustain East County Magazine's local reporting and/or wildfire alerts at https://www.eastcountymedia.org/donate to help us keep people safe and informed across our region.